The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 01, 2011
Filed:
Feb. 12, 2007
Malcolm Maccoss, Freehold, NJ (US);
David B. Olsen, Lansdale, PA (US);
Monica Donghi, Rome, IT;
Cristina Gardelli, Rome, IT;
Steven Harper, Rome, IT;
Malte Meppen, Rome, IT;
Frank Narjes, Rome, IT;
Barbara Pacini, Rome, IT;
Malcolm MacCoss, Freehold, NJ (US);
David B. Olsen, Lansdale, PA (US);
Monica Donghi, Rome, IT;
Cristina Gardelli, Rome, IT;
Steven Harper, Rome, IT;
Malte Meppen, Rome, IT;
Frank Narjes, Rome, IT;
Barbara Pacini, Rome, IT;
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., Pomezia, Rome, IT;
Abstract
The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.